CR20230479A - Formas de sales y sólidas de un inhibidor de cinasas - Google Patents

Formas de sales y sólidas de un inhibidor de cinasas

Info

Publication number
CR20230479A
CR20230479A CR20230479A CR20230479A CR20230479A CR 20230479 A CR20230479 A CR 20230479A CR 20230479 A CR20230479 A CR 20230479A CR 20230479 A CR20230479 A CR 20230479A CR 20230479 A CR20230479 A CR 20230479A
Authority
CR
Costa Rica
Prior art keywords
salt
solid forms
kinase inhibitor
forms
compound
Prior art date
Application number
CR20230479A
Other languages
English (en)
Spanish (es)
Inventor
Si Tuan Dong
Erika Butler
Nimita Dave
Brian Heinrich
Christopher Lee
Clare Aubrey Medendorp
Caitlin Kinkema
Lauren Maceachern
Hui Li
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CR20230479A publication Critical patent/CR20230479A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CR20230479A 2021-03-10 2022-03-10 Formas de sales y sólidas de un inhibidor de cinasas CR20230479A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163159107P 2021-03-10 2021-03-10
US202163208641P 2021-06-09 2021-06-09
PCT/US2022/019776 WO2022192558A1 (en) 2021-03-10 2022-03-10 Salt and solid forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
CR20230479A true CR20230479A (es) 2024-03-08

Family

ID=81074313

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230479A CR20230479A (es) 2021-03-10 2022-03-10 Formas de sales y sólidas de un inhibidor de cinasas

Country Status (11)

Country Link
US (1) US20240254130A1 (https=)
EP (1) EP4305036A1 (https=)
JP (1) JP2024509276A (https=)
KR (1) KR20240013720A (https=)
AU (1) AU2022234314A1 (https=)
BR (1) BR112023018246A2 (https=)
CA (1) CA3211477A1 (https=)
CR (1) CR20230479A (https=)
IL (1) IL305791A (https=)
MX (1) MX2023010606A (https=)
WO (1) WO2022192558A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230391780A1 (en) * 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
WO2024171143A1 (en) 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Salts and solid forms of elenestinib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021020441A2 (pt) 2019-04-12 2021-12-14 Blueprint Medicines Corp Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra

Also Published As

Publication number Publication date
US20240254130A1 (en) 2024-08-01
EP4305036A1 (en) 2024-01-17
BR112023018246A2 (pt) 2024-01-30
JP2024509276A (ja) 2024-02-29
CA3211477A1 (en) 2022-09-15
AU2022234314A1 (en) 2023-09-28
MX2023010606A (es) 2023-10-19
KR20240013720A (ko) 2024-01-30
WO2022192558A1 (en) 2022-09-15
IL305791A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
CR20220354A (es) Inhibidores de egfr
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
MX2024000230A (es) Inhibidores de cdk2.
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2021013981A (es) Inhibidores de la cinasa aurora y usos de los mismos.
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
EA202193015A1 (ru) Ингибиторы cdk
TW200800990A (en) Azaindole inhibitors of aurora kinases
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
MX2022006470A (es) Tiromimeticos novedosos.
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
SE0400284D0 (sv) Novel compounds
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
GEP20247655B (en) Crystalline salt forms of kinase inhibitor
PH12021552513A1 (en) Pyrrole compounds
CR20230479A (es) Formas de sales y sólidas de un inhibidor de cinasas
MX2024014312A (es) Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2021007258A (es) Composiciones de esparsentan amorfas.